Brief: Genmab Says Treatment With Rina-S Demonstrated Clinically Meaningful Objective Response Rate

Genmab A/S

05/10/2026 06:54

Oct 5 (Reuters) - Genmab A/S GMAB.CO:
SAID ON SATURDAY RINATABART SESUTECAN (RINA-S) PHASE 2 RAINFOL-01 RESULTS DEMONSTRATED DURABLE AND CLINICALLY MEANINGFUL RESPONSES IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER
ANTITUMOR ACTIVITY WAS OBSERVED REGARDLESS OF FOLATE RECEPTOR ALPHA (FRΑ) EXPRESSION LEVELS, INCLUDING LOW FRΑ EXPRESSION AND NON-EXPRESSORS
        
Source text 
Further company coverage: GMAB.CO 

(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))